Abstract: Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.

Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.

Abstract: An automated urine-output-measurement system can include single-patient equipment and/or multi-patient equipment. The single-patient equipment can include a urinary catheter and a urine-collection system. The urine-collection system can include drainage tubing and a drainage receptacle. The multi-patient equipment can include a urine monitor. The urine monitor can include a housing having a cavity configured to completely encompass the drainage receptacle, a urine measurement device configured to measure urine output into the drainage receptacle, and an integrated display screen configured to display patient information including measurements of the urine output. A method of the automated urine-output-measurement system can include placing the drainage receptacle in the urine monitor of the automated urine-output-measurement system, and confirming a volume of urine in the drainage receptacle with that indicated on the urine monitor once a patient has produced urine.

Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

Abstract: An automated urine-output-measurement system can include single-patient equipment and multi-patient equipment. The single-patient equipment can include a urinary catheter and a urine-collection system. The urine-collection system can include drainage tubing and a drainage receptacle. The multi-patient equipment can include a urine monitor. The urine monitor can include a housing having a cavity configured to house the drainage receptacle, a urine-measurement means for measuring urine-output into the drainage receptacle, and an integrated display screen configured to display patient information including measurements of the urine output. A method of the automated urine-output-measurement system can include placing the drainage receptacle in the urine monitor of the automated urine-output-measurement system, and confirming a volume of urine in the drainage receptacle with that indicated on the urine monitor once a patient has produced urine.

Abstract: A hemostasis valve device includes a valve body having an open first end and an open second end with a main lumen extending from the open first end to the open second end. The valve includes a valve member disposed within the main lumen of the valve body at or proximate to the open first end, the valve member having an open position and a closed position. An actuator is disposed between the valve member and the open second end. The actuator is configured to move the valve member between the open position and the closed position.

Abstract: Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

Abstract: A wind turbine is optimized for low and high speed winds with sensing to measure climate change gases using IoT connectivity with long life serviceability. The wind turbine has an egg-shaped or elliptical profile that performs well in any physical orientation, enabling plural turbines in either horizontal or vertical stacks. A wildlife net is applied to the intake sides of the wind turbine, where the profile secures the net against displacement.

Abstract: An automated urine-output-measurement system can include single-patient equipment and multi-patient equipment. The single-patient equipment can include a urinary catheter and a urine-collection system. The urine-collection system can include drainage tubing and a drainage receptacle. The multi-patient equipment can include a urine monitor. The urine monitor can include a housing having a cavity configured to house the drainage receptacle, a urine-measurement means for measuring urine-output into the drainage receptacle, and an integrated display screen configured to display patient information including measurements of the urine output. A method of the automated urine-output-measurement system can include placing the drainage receptacle in the urine monitor of the automated urine-output-measurement system, and confirming a volume of urine in the drainage receptacle with that indicated on the urine monitor once a patient has produced urine.

Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.

Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.

Abstract: Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.

Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

Abstract: Wrist, hand, or arm support devices are provided. The support devices include a support member having a top surface and a front surface. The top surface is oriented at either a parallel angle or a non-parallel angle with respect to a work surface. The front surface curves upon itself to form either a symmetric or an asymmetric arc. Preferred versions of the support devices described herein include at least one of a top surface oriented at a non-parallel angle with respect to the work surface or a front surface that curves upon itself to define an asymmetric arc. Mounting members for connecting the support member to an operating surface are also provided. The support devices described herein permit an operator to comfortably rest his or her hand on the support devices while directing procedures toward non-centered portions of work objects.

Abstract: Wrist, hand, or arm support devices are provided. The support devices include a support member having a top surface and a front surface. The top surface is oriented at either a parallel angle or a non-parallel angle with respect to a work surface. The front surface curves upon itself to form either a symmetric or an asymmetric arc. Preferred versions of the support devices described herein include at least one of a top surface oriented at a non-parallel angle with respect to the work surface or a front surface that curves upon itself to define an asymmetric arc. Mounting members for connecting the support member to an operating surface are also provided. The support devices described herein permit an operator to comfortably rest his or her hand on the support devices while directing procedures toward non-centered portions of work objects.